Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients

摘要

Abstract Background aims A strategy to improve the low rate of anti‐SARS‐CoV‐2 mRNA vaccine‐induced immunogenicity in liver transplant recipients (LTs) is urgently needed. Methods We analysed the rate of positive (≥0.8?U/ml) anti‐SARS‐CoV‐2 receptor domain‐binding protein (RBD) antibody response 2?months after a third dose of the BNT16b2 vaccine in 107 LTs who completed the second vaccine dose 7?months earlier. Results A positive anti‐SARS‐CoV‐2‐s‐RBD antibody response after the third vaccine dose was detected in 98 (91.6) LTs compared to 82 (76.6) after the second vaccine dose (p?=?.003). The median of anti‐SARS‐CoV‐2 RBD antibody titres increased from 22.9?U/ml 6?months after the second to 3500?U/ml 2?months after the third vaccine dose (p?